Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate efficacy, safety of administered DWP05195 in Postherpetic Neuralgia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

NCT00245544

Neuralgia, Postherpetic

TERMINATED PHASE2

To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)

NCT05357677

Postherpetic Neuralgia

COMPLETED PHASE2

Study in Neuropathic Pain Patients With Peripheral Nerve Injury

NCT00969059

Pain, Neuropathic

COMPLETED PHASE2

A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419

NCT04494815

Peripheral Neuropathic Pain

COMPLETED PHASE1/PHASE2

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

NCT00034710

Neuralgia Pain Peripheral Nervous System Diseases +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postherpetic Neuralgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A

Group Type EXPERIMENTAL

DWP05195

Intervention Type DRUG

Tablets, oral administration, 100mg

Treatment B

Group Type EXPERIMENTAL

DWP05195

Intervention Type DRUG

Tablets, oral administration, 200mg

Treatment C

Group Type EXPERIMENTAL

DWP05195

Intervention Type DRUG

Tablets, oral administration, 300mg

Treatment D

Group Type PLACEBO_COMPARATOR

Control

Intervention Type DRUG

Tablets, oral administration, Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DWP05195

Tablets, oral administration, 100mg

Intervention Type DRUG

DWP05195

Tablets, oral administration, 200mg

Intervention Type DRUG

DWP05195

Tablets, oral administration, 300mg

Intervention Type DRUG

Control

Tablets, oral administration, Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female subjects aged 20 to 80 years
* Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia(PHN).
* Subjects must have pain present for \> 3 months after healing of the acute herpes zoster skin rash.

Exclusion Criteria

* Other severe pain that may potentially confound pain assessment.
* Subjects with symptoms of neuropathic pain applied Medical Equipment
* Within 2 years: Subjects were diagnosed with cancer

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No